9 Meters Biopharma
NMTR
NMTR was delisted on the 25th of July, 2023.
57 hedge funds and large institutions have $52.2M invested in 9 Meters Biopharma in 2020 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 14 increasing their positions, 5 reducing their positions, and 9 closing their positions.
180% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 5
167% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 9
126% more capital invested
Capital invested by funds: $23.1M → $52.2M (+$29.1M)
36% more funds holding
Funds holding: 42 → 57 (+15)
31% less call options, than puts
Call options by funds: $915K | Put options by funds: $1.33M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$10.8M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.36M |
| 3 |
BlackRock
New York
|
+$2.3M |
| 4 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$658K |
| 5 |
MS
Maven Securities
St Helier,
Jersey
|
+$626K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$625K |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$149K |
| 3 |
ECM
ExodusPoint Capital Management
New York
|
-$112K |
| 4 |
Squarepoint
New York
|
-$99K |
| 5 |
Two Sigma Investments
New York
|
-$92K |
NMTR Hedge Fund Activity: Q4 2020 in Review
57 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in 9 Meters Biopharma (NMTR) for Q4 2020, worth a combined $52.2M — up 126% from $23.1M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new NMTR positions and 9 closed out — a net gain of 15 holders — while 14 added to existing stakes and 5 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $10.8M. The largest seller was Millennium Management, cutting an estimated $625K.
- 57 institutional investors held 9 Meters Biopharma (NMTR) as of Q4 2020, up from 42 in Q3 2020.
- Funds reported $52.2M of 9 Meters Biopharma stock for Q4 2020, up 126% quarter-over-quarter.
- 24 funds opened new 9 Meters Biopharma positions in Q4 2020 and 9 closed out, a net change of +15 holders.
- The largest 9 Meters Biopharma buyer in Q4 2020 was Adage Capital Partners, an estimated $10.8M added.
- The largest 9 Meters Biopharma seller in Q4 2020 was Millennium Management, an estimated $625K sold.
Based on aggregated 13F filings for Q4 2020.